FASEB SRC: The Consequences of Aneuploidy: Honoring the Contributions of Angelika Amon

摘要 我们正在申请资助一个新的FASEB会议，题为“非整倍性的后果： 纪念安吉丽卡·阿蒙的贡献。”本次大会将于2022年9月11日至16日举行， 在马萨诸塞州的南桥。这次会议的主要目标有两个：第一，使 世界领先的研究非整倍体后果的专家，第二，荣誉的贡献， Angelika Amon是非整倍体研究的先驱，她于2020年因卵巢癌去世。 非整倍性，或染色体拷贝数不是正常生物体的整数倍的状态 单倍体补体是恶性生长的标志，是智力低下最常见的遗传原因。 残疾。目前基于测序的估计表明，高达90%的人类肿瘤表现出非整倍体， 高水平的非整倍性与转移性疾病、耐药性和令人沮丧的患者结果有关。 尽管非整倍体在癌症中普遍存在，并且对人类健康具有重要意义，但没有规律性的非整倍体。 会议在美国致力于分享这类基因组改变的最新进展。 我们的目标是建立一个关于这个主题的新会议，作为一个论坛，汇集科学家分享 在这个令人兴奋和快速发展的领域的最新进展。本次会议的组织团队包括： 非整倍体研究的领军人物，他们是安吉丽卡的同事和实习生， 会议在她的记忆。该团队已经获得了FASEB对本次会议的支持， 为活动提供重要的组织、后勤和技术支持。R13资助计划 要求补贴早期职业研究人员和代表性不足的研究人员的费用 背景参加这次活动。我们目前有41个确认的发言者，涉及10个主题领域， 非整倍体和染色体分离，特别关注非整倍体对肿瘤的影响 发展和人类健康。计划为早期职业科学家提供更多的节目，包括一系列 简短的演讲，两个海报会议，和几个职业发展活动。

Abstract We are requesting grant support for a new FASEB conference entitled “The Consequences of Aneuploidy: Honoring the Contributions of Angelika Amon.” This conference will be held from September 11th to 16th, 2022, in Southbridge, Massachusetts. The broad goals for this conference are two-fold: first, to bring together the world’s leading experts in studying the consequences of aneuploidy, and second, to honor the contributions of Angelika Amon, a pioneer of aneuploidy research who passed away from ovarian cancer in 2020. Aneuploidy, or a chromosome copy number state that is not a whole-number multiple of an organism’s normal haploid complement, is a hallmark of malignant growth and is the most common genetic cause of intellectual disability. Current sequencing-based estimates suggest that up to 90% of human tumors exhibit aneuploidy, and high levels of aneuploidy are associated with metastatic disease, drug resistance, and dismal patient outcomes. Despite the ubiquity of aneuploidy in cancer and its significance to human health, there are no regular conferences in the United States dedicated to sharing the latest advances on this class of genomic alterations. We aim to establish a new conference on this topic that will serve as a forum to bring together scientists to share the latest advances in this exciting and fast-moving field. The organizing team for this conference consists of leading aneuploidy researchers who were Angelika’s colleagues and trainees and are convening this inaugural conference in her memory. This team has already secured the support of FASEB for this conference, which will provide significant organizational, logistic, and technical support for the event. R13 grant funding is being requested to subsidize the costs for early-career researchers and researchers from under-represented backgrounds to attend this event. We currently have 41 confirmed speakers across 10 topic areas related to aneuploidy and chromosome segregation, with a particular focus on the impact of aneuploidy on tumor development and human health. Additional programming is planned for early-career scientists, including a series of short talks, two poster sessions, and several career-development events.